X-37 is a pharmaceutical discovery and development company leveraging AI to innovate drug development. Co-founded by AtomWise and pharmaceutical experts from Velocity Pharmaceutical Development, X-37 focuses on targeting difficult-to-drug proteins with high therapeutic value. Their AI-driven approach enables them to address challenging targets in autoimmune diseases, cancer, and anticoagulation, aiming to create safe and effective therapies where conventional methods have struggled.
X-37 has achieved significant milestones, including closing a $14.5 million Series A financing led by DCVC Bio, with participation from Alpha Intelligence Capital and Hemi Ventures. This funding supports their mission to revolutionize drug discovery using advanced AI technology. The company's impactful work has already sparked new hope for treating complex diseases, positioning X-37 as a leader in AI-driven pharmaceutical innovation.
